News

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter, August 2022
Volume17
Issue 8

Discovery Life Sciences Acquires AllCells

Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.

Discovery Life Sciences (Discovery), a company specializing in biomarkers and biospecimens, announced its acquisition of AllCells, a provider of human primary blood and marrow-based cells. Discovery plans to combine its existing cell and gene therapy products and services with AllCells to create a business unit called AllCells, a Discovery Life Sciences company. AllCells CEO and President Danny Zheng will lead the entity.

“We are very excited to welcome the AllCells team to the Discovery family,” said Glenn Bilawsky, CEO, Discovery Life Sciences, in a July 12, 2022 company press release. “Bringing these two great companies together creates a scalable, end-to-end solution that gives our clients unprecedented access to reliable human cellular starting materials with integrated multi-omic analytic services to support cell and gene therapies.”

According to the press release, the acquisition grants Discovery access not only to their cell supplies, but also starting materials and analytic services to accelerate cell and gene therapy experiences. Additionally, Discovery’s newly acquired FDA-registered donor collection facilities and good manufacturing practice (GMP)-compliant cleanrooms are adjacent to characterization labs; this placement enables immediate processing and cryopreservation.

“We have built our organization to be an extension of our client's supply chain. By offering donor program consulting, high-quality apheresis collections, customization services, and GMP-compliant starting materials, our dedicated team will continue to provide a high-touch, client-focused approach to ensure our clients' needs are met with superior products and services to fit any timeline and on any scale,” said Zheng in the press release. “Our strategy parallels and reinforces Discovery's 'Science at your Service' approach, and our unified offerings will further accelerate our clients' strategic and vital cell and gene therapy programs.”

Source: Discovery Life Sciences

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content